Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002–2012 Literature Review
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus ( DM ) is one of the most common chronic conditions in older adults and is often accompanied by comorbidities and geriatric syndromes. The management of cardiovascular disease risk factors in older adults with DM is important to clinicians. The literature was reviewed from 2002 to 2012 to provide an American Geriatrics Society expert panel with an evidence base for updating and making new recommendations for improving the care of older adults with type 2 DM . This review includes only the domains of the management of blood pressure, lipid control, glycemic control, and use of aspirin. Over the last 10 years, new randomized controlled trials ( RCT ) designed to study different blood pressure treatment targets did not find evidence that intensive systolic blood pressure control (<130 mmHg) resulted in lower rates of myocardial infarction and mortality than less‐intensive control. There are risks of side effects with achieving systolic blood pressure of less than 120 mmHg. Lipid‐lowering statins are effective in reducing cardiovascular events in middle‐aged and older adults, but data on niacin and fibrates is limited. Trials of statins and other lipid‐lowering agents do not evaluate the cardiovascular effects on outcomes from treating lipids to different low‐density lipoprotein cholesterol targets. No RCT s of lipid‐lowering drugs enrolled significant numbers of adults aged 80 and older with or without DM . Three major RCT s that investigated intensive glycemic control did not find reductions in primary cardiovascular endpoints, and one study reported greater mortality with glycosylated hemoglobin of less than 6%. Two recently published RCT s were designed to study the cardiovascular benefits of aspirin use by individuals with DM . Neither trial found significantly fewer primary cardiovascular endpoints with aspirin than in control groups. Overall, RCT s enrolled few adults aged 80 and older or with significant comorbidities. More research is needed for clinicians to effectively customize care to older adults with DM because of heterogeneity in health status, comorbidities, duration of disease, frailty and functional status, and differences in life expectancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“Finally, two large meta-analyses of 18,686 and 5,963 people with DM that found significant reductions in cardiovascular events and all cause mortality were reviewed.(31,32) RCTs that have examined the effect of statins on CVD endpoints and mortality have largely excluded adults aged 80 and older.”
BackgroundEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“niacin that did not show fewer primary cardiovascular outcomes with the intensive therapy.(29,30) Finally, two large meta-analyses of 18,686 and 5,963 people with DM that found significant reductions in cardiovascular events and all cause mortality were reviewed.”
BackgroundCollaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · cited 1×
“Finally, two large meta-analyses of 18,686 and 5,963 people with DM that found significant reductions in cardiovascular events and all cause mortality were reviewed.(31,32) RCTs that have examined the effect of statins on CVD endpoints and mortality have largely excluded adults aged 80 and older.”
BackgroundA Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035 · cited 1×
“In the ACCORD-BP trial, hypoglycemia was more common in older adults, and greater mortality was found in the intensive glucose control group than in the lessintensive usual care group.(36,37) The RCTs reviewed do not provide supportive evidence that intensive glycemic control (HbA1c <6% or <6.”
BackgroundGæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · cited 1×
“Studies that target the control of multiple risk factors are not addressed because they were found to be limited.(2,3) RESULTS Research on Blood Pressure Management Older adults with DM have a high prevalence of hypertension, and complications of hypertension are independent from those of hyperglycemia.”
BackgroundBelch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762 · cited 1×
“A United Kingdom Prospective Diabetes Study (UKPDS) follow-up study on the long-term benefits after tight blood pressure control determined that there were no macrovascular benefits if tight blood pressure control was not sustained.(10) Recent large subgroup post hoc analysis of the International Verapamil SR-Trandola…”
BackgroundGuidelines for improving the care of the older person with diabetes mellitus
California Healthcare Foundation/American Geriatrics Society, C. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.51.5s.1.x · Cited by 651
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J., & Group, F. T. S. S. S. (1997) · Circulation · doi:10.1161/01.cir.96.12.4211 · Cited by 508
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390
Systematic review: glucose control and cardiovascular disease in type 2 diabetes
Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., & He, J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-6-200909150-00137 · Cited by 358
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., Wang, K., Zou, Y., & Ge, J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.029 · Cited by 150
McBrien, K., Rabi, D. M., Campbell, N., Barnieh, L., Clement, F., Hemmelgarn, B. R., Tonelli, M., Leiter, L. A., Klarenbach, S. W., & Manns, B. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3147 · Cited by 129 · cited 2×
“The meta-analyses found an association between lower blood pressure and risk of stroke, but this was in the setting of more serious adverse events.(15,16) Research on Control of Lipids Numerous RCTs have demonstrated the benefits of statins in the primary and secondary prevention of CVD and reducing cardiovascular mor…”
BackgroundMethodBlood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial
Anderson, R. J., Bahn, G. D., Moritz, T. E., Kaufman, D., Abraira, C., Duckworth, W., & for the VADT Study Group (2011) · Diabetes Care · doi:10.2337/dc10-1420 · Cited by 93
Research works printed but not linked: 27
- 10.1001/jama.299.14.1678 · DOI · Paper page
- 10.1046/j.1523-1755.2002.00213.x · DOI · Paper page
- 10.1136/bmj.317.7160.703 · DOI · Paper page
- Ninomiya T, 2010, Efficacy and safety of routine blood pressure lowering in older patients with diabetes: Results from the ADVANCE trial, J Hypertens, 28, 1141, 10.1097/HJH.0b013e328338a89c · DOI · Paper page
- 10.1097/HJH.0b013e32832d7370 · DOI · Paper page
- 10.1001/jama.2010.884 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.110.016337 · DOI · Paper page
- 10.1056/NEJM199610033351401 · DOI · Paper page
- 10.1056/NEJM199811053391902 · DOI · Paper page
- 10.1016/S0140-6736(02)09327-3 · DOI · Paper page
- 10.1001/archinte.162.12.1395 · DOI
- 10.1001/jama.279.20.1615 · DOI · Paper page
- 10.2337/dc05-2415 · DOI · Paper page
- 10.1056/NEJMoa0806470 · DOI · Paper page
- 10.1056/NEJMoa0802743 · DOI · Paper page
- 10.1056/NEJMoa0802987 · DOI · Paper page
- 10.1016/S0140-6736(09)60697-8 · DOI · Paper page
- 10.1016/j.numecd.2009.03.021 · DOI · Paper page
- ET‐DRS Investigators, 1992, Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14, JAMA, 268, 1292, 10.1001/jama.1992.03490100090033 · DOI · Paper page
- 10.1136/bmj.296.6618.313 · DOI · Paper page
- 10.1056/NEJM198907203210301 · DOI · Paper page
- 10.1016/S0140-6736(97)11475-1 · DOI · Paper page
- 10.2337/diacare.26.12.3264 · DOI · Paper page
- 10.2337/dc09-1297 · DOI · Paper page
- 10.1097/MAJ.0b013e3181f1fba8 · DOI
- 10.2337/dc10-0555 · DOI · Paper page
- 10.1186/1745-6215-8-21 · DOI · Paper page
Cited by
Immunosenescence and vaccine failure in the elderly: strategies for improving response
Boraschi, D., & Italiani, P. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.06.006 · Cited by 86
Bailey, R. A., Pfeifer, M., Shillington, A. C., Harshaw, Q., Funnell, M. M., VanWingen, J., & Col, N. (2015) · BMC Health Services Research · doi:10.1186/s12913-016-1262-4 · Cited by 84
Pasquel, F. J., Powell, W., Peng, L., Johnson, T. M., Sadeghi-Yarandi, S., Newton, C., Smiley, D., Toyoshima, M. T., Aram, P., & Umpierrez, G. E. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000104 · Cited by 44
Leung, V., Wroblewski, K., Schumm, L. P., Huisingh-Scheetz, M., & Huang, E. S. (2021) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glab141 · Cited by 21
Metadata
- Authors
- Moreno, G., & Mangione, C. M.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2013-11
- Volume
- 61
- Issue
- 11
- Pages
- 2027-2037
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2029338738
- Cited by
- 65
- References
- 32
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institute on Aging (K23 AG042961-01)
- American Federation for Aging Research
- Hartford Foundation
- National Institute on Minority Health and Health Disparities (R01-MD0061850-02)
- National Institutes of Health (P30-AG021684)
- National Center for Advancing Translational Sciences UCLA Clinical and Translational Science Institute (UL1TR000124)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.